drugset / Trial / NCT02218034

Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne Vulgaris

NCT02218034

Phase 1 Completed 78 enrolled Allergan
RandomizedParallel-groupSingle-blindBasic science

Summary

This is a safety, tolerability and pharmacokinetics study of AGN-190168 in subjects with acne vulgaris.

Timeline

Start
2014-08
Primary completion
2015-03
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Subject AGN-190168 Formulation 1 Unknown Topical
Subject AGN-190168 Formulation 2 Unknown Topical
Comparator Tazarotene Small molecule 0.1 % Topical

Indications